OncoHost is advancing a new paradigm in precision oncology.
The PROphet® platform combines AI and plasma proteomic profiling to assign a PROphet® Score, a
measure of the predicted clinical benefit from anti-PD-1/PD-L1 treatment correlated to the patient’s
overall survival, and list clinical evidence-based treatment considerations.
The PROphet® platform combines AI and plasma proteomic profiling to assign a PROphet® Score, a
measure of the predicted clinical benefit from anti-PD-1/PD-L1 treatment correlated to the patient’s
overall survival, and list clinical evidence-based treatment considerations.
Plasma Proteomic Profiling
Analyzing the biological interplay of the patient, tumor, and therapy can:
Enable early prediction
of individual response to
anti-PD-1/PD-L1 immunotherapy
of individual response to
anti-PD-1/PD-L1 immunotherapy
Provide actionable
clinical insights and
optimal therapy choices
clinical insights and
optimal therapy choices
A new approach to
managing therapeutic strategies
Blood-based test
Not exclusive to
mutation carriers
mutation carriers
Personalized
PROphet® Report
PROphet® Report
Predictive
clinical insights
clinical insights
Clinical evidence-
based treatment
considerations
based treatment
considerations